[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100539701":3},{"organization":4,"outcomesModule":7,"designInfo":50,"detailedDescription":51,"studyPopulation":52,"armGroups":11,"interventions":53,"overallOfficials":11,"centralContacts":60,"locations":69,"responsibleParty":86,"collaborators":11,"id":90,"slug":11,"hasResults":91,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":95,"eligibilityCriteria":96,"healthyVolunteers":91,"sex":97,"minAge":98,"maxAge":11,"enrollmentInfo":99,"targetDuration":102,"studyType":103,"phases":11,"briefSummary":104,"conditions":105,"keywords":109,"overallStatus":71,"whyStopped":11,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":122},{"fullName":5,"class":6},"LMU Klinikum","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"All-cause mortality",null,"5 years",[14,17,20,23,26,29,32,35,38,41,44,47],{"measure":15,"description":16,"timeFrame":12},"Technical success","absence of procedural mortality, successful access, delivery and retrieval of the delivery system, successful deployment and positioning, freedom from emergency surgery",{"measure":18,"description":19,"timeFrame":12},"Procedural Safety","periprocedural and in-hospital adverse events",{"measure":21,"description":22,"timeFrame":12},"Heart Failure Biomarker","NT-proBNP level",{"measure":24,"description":25,"timeFrame":12},"Dyspnea on exertion","New York Heart Association (NYHA) functional class",{"measure":27,"description":28,"timeFrame":12},"Functional capacity","6-minute walk distance (6MWD)",{"measure":30,"description":31,"timeFrame":12},"Right ventricular size","Mid-ventricular diameter of the right ventricle measured by echocardiography",{"measure":33,"description":34,"timeFrame":12},"Right ventricular function","Right ventricular fractional area change measured by echocardiography",{"measure":36,"description":37,"timeFrame":12},"Tricuspid regurgitation reduction","Tricuspid regurgitation severity measured by echocardiography",{"measure":39,"description":40,"timeFrame":12},"Tricuspid valve stenosis","Transvalvular pressure gradient measured by echocardiography",{"measure":42,"description":43,"timeFrame":12},"Pulmonary hypertension","Pulmonary artery pressure measured by echocardiography",{"measure":45,"description":46,"timeFrame":12},"Right heart congestion","Inferior vena cava dimensions measured by echocardiography",{"measure":48,"description":49,"timeFrame":12},"Hospitalization for heart failure","Date and number of heart failure hospitalizations after the index procedure",{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":6,"timePerspective":6,"maskingInfo":11},"Background and Rationale:\n\nTricuspid regurgitation (TR) is a major health and economic burden due to high rates of heart failure hospitalizations, morbidity and mortality. Surcial treatment of TR is associated with high procedural and in-hospital mortality. Due to prohibitive surgical risk, a significant proportion of patients historically remained untreted beyond medical therapy. Transcatheter tricuspid valve (TV) repair and replacement techniques (TTVT) now offer a new treatment perspective for these patients. The EuroTR registry aims at optimizing patient selection prior to TTVT and thus treatment quality by collecting respective data in a real-world setting.\n\nObjectives:\n\nTo investigate clinical and survival outcome following transcatheter tricuspid valve repair or replacement.","Patients treated with one of the following transcatheter devices for TV repair or replacement (e.g. PASCAL, TriClip, TricValve, Evoque, LuX-Valve)",[54],{"type":55,"name":56,"description":57,"armGroupLabels":11,"otherNames":58},"DEVICE","T-TEER","T-TEER using the PACAL or TriClip device",[59],"Transcatheter tricuspid valve edge-to-edge repair",[61,66],{"name":62,"role":63,"phone":64,"phoneExt":11,"email":65},"Jörg Hausleiter, Prof. Dr.","CONTACT","+49 89 4400 72360","Joerg.Hausleiter@med.uni-muenchen.de",{"name":67,"role":63,"phone":11,"phoneExt":11,"email":68},"Lukas Stolz, Dr.","Lukas.Stolz@med.uni-muenchen.de",[70],{"facility":5,"status":71,"city":72,"state":73,"zip":74,"country":75,"countryCode":76,"cosmosGeoPoint":77,"geoPoint":82,"contacts":83},"RECRUITING","Munich","Bavaria","81377","Germany","DE",{"type":78,"coordinates":79},"Point",[80,81],11.57549,48.13743,{"lat":81,"lon":80},[84,85],{"name":62,"role":63,"phone":64,"phoneExt":11,"email":65},{"name":67,"role":63,"phone":11,"phoneExt":11,"email":68},{"type":87,"investigatorFullName":88,"investigatorTitle":89,"investigatorAffiliation":5,"oldNameTitle":11,"oldOrganization":11},"PRINCIPAL_INVESTIGATOR","Prof. Dr. med. Jörg Hausleiter","Deputy chief","100539701",false,"NCT06307262","European Registry of Transcatheter Repair for Tricuspid Regurgitation","European Registry of Transcatheter Repair for Tricuspid Regurgitation (EuroTR)","EuroTR","Inclusion Criteria:\n\n* Patients treated with one of the following transcatheter devices for TV repair or replacement: PASCAL, TriClip, TricValve, Evoque, LuX-Valve\n* Age ≥ 18 years","ALL","18 Years",{"count":100,"type":101},3000,"ESTIMATED","5 Years","OBSERVATIONAL","To investigate clinical and survival outcomes following transcatheter tricuspid valve repair or replacement.",[106,107,108],"Tricuspid Regurgitation","Valvular Heart Disease","Heart Failure",[110,111,112],"Tricuspid regurgitation","TEER","edge-to-edge repair","2024-03-13",{"date":115,"type":116},"2024-03-15","ACTUAL",{"date":118,"type":116},"2023-10-23",{"date":120,"type":101},"2030-12-31",{"name":5,"class":6},1]